Category: Imaging & mpMRI

Combining multiparametric MRI with genomic testing is revolutionizing prostate cancer detection and treatment. By leveraging the strengths of both technologies, doctors can achieve more accurate diagnoses, guide personalized treatment decisions, and improve patient outcomes. Learn how these tools are shaping the future of prostate cancer care. keep reading

Skip the contrast agent, and a prostate MRI gets faster and cheaper, but it loses the one signal that makes cancer impossible to miss: abnormal blood flow. That trade-off is why the third MRI sequence matters, and why a newly approved low-dose contrast agent is worth watching. It offers the same vascular proof with a fraction of the gadolinium. keep reading

What makes one prostate biopsy better than another? It often comes down to two things: how clearly the doctor can see the target, and how many needles it takes to reach it. Real-time MRI guidance can pinpoint a suspicious lesion with just a few samples, while older methods rely on more needles and more guesswork. Accuracy and safety both hang on that choice. keep reading

As many as 75% of PSA tests come back falsely positive, and for years that single number sent men straight to a needle biopsy with all its risks. Today, noninvasive biomarker tests in blood and urine, paired with mpMRI, are reshaping who truly needs the procedure and who can safely be spared the discomfort and the worry. keep reading

For decades, men have faced a coin flip after a high PSA result: biopsy or nothing. A major study of nearly 18,000 men suggests there's a smarter middle step — MRI. Used as a filter between PSA and biopsy, it identifies who truly needs further evaluation and cuts unnecessary overtreatment in half. keep reading

Focal therapy destroys a prostate tumor while leaving healthy tissue intact. But once treatment is done, how do doctors know if it worked? A structured follow-up protocol using mpMRI is the current standard. Now a newly proposed PSMA-based scoring system called PSMA-FAB is aiming to complement that approach. keep reading

A prostate MRI can detect cancer without contrast but how confident can a doctor be? DCE-MRI adds a third layer of information by capturing tumor blood flow patterns that plain MRI can't show. Gadolinium makes this possible, and modern formulations have an impressive safety record: over 170 million doses studied. keep reading

A high PSA result sounds alarming but it doesn't automatically mean cancer. Other factors can raise PSA, and until recently, the only way to know more was a biopsy. Now, two major breakthroughs are reshaping prostate cancer screening in ways that protect men from unnecessary procedures. keep reading

Multifocality has shaped prostate cancer treatment for years, but research shows some cases are unifocal and may qualify for less invasive focal therapy. Careful clinical evaluation is key to tailoring the best treatment approach. keep reading

Traditional PSA screening can lead to overdetection and unnecessary biopsies due to its lack of specificity for prostate cancer. New research highlights biparametric MRI as a promising, quicker, and potentially more accurate first-line screening tool. keep reading